- Alnylam gets surprise FDA rejection for rare disease drug – Boston Business Journal The Business Journals
- Alnylam abandons Onpattro expansion in US as FDA spurns rare heart disease bid FiercePharma
- FDA rejects Alnylam’s request to expand approval of one of its drugs to include heart patients The Boston Globe
- Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval Yahoo News
- Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Business Wire
Tag Archives: FDA
After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy’s Alfasigma – FiercePharma
- After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy’s Alfasigma FiercePharma
- Intercept, once a biotech trailblazer, sells itself for less than $1 billion STAT
- Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases Yahoo Finance
- Why Intercept Pharmaceuticals Stock Is Skyrocketing Today The Motley Fool
- Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today? InvestorPlace
- View Full Coverage on Google News
Major Trial Finds MDMA-Assisted Therapy Is Effective for PTSD, Paving Way for FDA Approval – Gizmodo
- Major Trial Finds MDMA-Assisted Therapy Is Effective for PTSD, Paving Way for FDA Approval Gizmodo
- Psychedelic drug MDMA eases PTSD symptoms in a study that paves the way for possible US approval The Associated Press
- MDMA Therapy for PTSD Inches Closer to U.S. Approval The New York Times
- MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study Pharmacy Times
- After Latest Clinical Trial, MDMA Therapy For PTSD Is ‘On Track’ For FDA Consideration Next Year Marijuana Moment
- View Full Coverage on Google News
Stuffy or runny nose? Don’t bother using popular nasal decongestant: US FDA – Global News
- Stuffy or runny nose? Don’t bother using popular nasal decongestant: US FDA Global News
- Decongestant found in Sudafed PE, Vicks Dayquil and others doesn’t work, FDA panel says. Here’s why and what you should use instead of phenylephrine. Yahoo Life
- FDA says popular decongestant doesn’t work | WNN ABC News
- FDA: Phenylephrine, ingredient found in decongestants, determined to be ineffective CBS Pittsburgh
- Popular nasal decongestants like Sudafed, NyQuill are ineffective, FDA says | LiveNOW from FOX LiveNOW from FOX
- View Full Coverage on Google News
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma – PR Newswire
- Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma PR Newswire
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy – TipRanks.com TipRanks
- Delcath Systems Stock Is Rocketing Higher: What’s Going On? – Delcath Systems (NASDAQ:DCTH) Benzinga
- Why Is Delcath Systems (DCTH) Stock Up 72% Today? InvestorPlace
- Persistence pays for Delcath as cancer treatment Hepzato Kit finally scores FDA nod FiercePharma
- View Full Coverage on Google News
Sage suggests job and pipeline cuts after FDA rejection of major depression pill – Endpoints News
- Sage suggests job and pipeline cuts after FDA rejection of major depression pill Endpoints News
- Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug CNBC
- Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder MarketWatch
- Why Sage Therapeutics Shares Are Sinking Monday – Sage Therapeutics (NASDAQ:SAGE) Benzinga
- Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Yahoo Finance
- View Full Coverage on Google News
Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder – MarketWatch
- Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder MarketWatch
- Sage Therapeutics stock plunges more than 50% after FDA decision on postpartum depression drug CNBC
- Sage Stock: Why The Biotech Lost Half Its Value After The FDA Approved Its Depression Drug Investor’s Business Daily
- Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Yahoo Finance
- Why Sage Therapeutics Shares Are Sinking Monday – Sage Therapeutics (NASDAQ:SAGE) Benzinga
- View Full Coverage on Google News
FDA clears Braeburn’s long-acting Brixadi to treat opioid use disorder – FiercePharma
- FDA clears Braeburn’s long-acting Brixadi to treat opioid use disorder FiercePharma
- FDA Approves Braeburn’s Brixadi Injection to Treat Moderate-to-Severe Opioid Use Disorder Pharmacy Times
- Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder PR Newswire
- Indivior’s Opvee crosses FDA finish line, adding new overdose rescue option amid raging opioid epidemic FiercePharma
- FDA Approves Buprenorphine Injection for Opioid Use Disorder Medscape
- View Full Coverage on Google News
New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval – Yahoo! Voices
- New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval Yahoo! Voices
- Decision made on RX nasal spray for opioid overdoses WJW FOX 8 News Cleveland
- New overdose antidote approved, but concerns raised about cost, side effects The Washington Post
- Indivior’s Opvee crosses FDA finish line, adding new overdose rescue option amid raging opioid epidemic FiercePharma
- Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder PR Newswire
- View Full Coverage on Google News
FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy – STAT
- FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy STAT
- Krystal’s Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease FiercePharma
- Rare Skin Blistering Condition Gets First Drug Approved Medpage Today
- Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB). Business Wire
- FDA Approves First-Ever Topical Gene Therapy Medscape
- View Full Coverage on Google News